These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17909805)

  • 1. A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
    Yong WP; Wang LZ; Tham LS; Wong CI; Lee SC; Soo R; Sukri N; Lee HS; Goh BC
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):243-51. PubMed ID: 17909805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug.
    Tham LS; Lee HS; Wang L; Yong WP; Fan L; Ong AB; Sukri N; Soo R; Lee SC; Goh BC
    Ther Drug Monit; 2006 Apr; 28(2):255-61. PubMed ID: 16628140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study.
    Van Veldhuizen PJ; Reed G; Aggarwal A; Baranda J; Zulfiqar M; Williamson S
    Cancer; 2003 Nov; 98(9):1855-62. PubMed ID: 14584067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
    Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
    Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
    Engels FK; Mathot RA; Loos WJ; van Schaik RH; Verweij J
    Cancer Biol Ther; 2006 Jul; 5(7):833-9. PubMed ID: 16775418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.
    Chen M; Nafziger AN; Bertino JS
    Drug Metab Dispos; 2006 Dec; 34(12):2079-82. PubMed ID: 16997909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer.
    Hilli J; Sailas L; Jyrkkiö S; Pyrhönen S; Laine K
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1353-62. PubMed ID: 20798939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
    Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
    Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of ketoconazole on the fecal and urinary disposition of docetaxel.
    Engels FK; Loos WJ; Mathot RA; van Schaik RH; Verweij J
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):569-79. PubMed ID: 17256132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.
    Ayan-Oshodi MA; Willis BA; Annes WF; Lowe SL; Friedrich S; de la Peña A; Zhang W; Brown T; Wise SD; Hall SD
    Drug Metab Dispos; 2012 Oct; 40(10):1945-52. PubMed ID: 22789530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
    Machiels JP; Staddon A; Herremans C; Keung C; Bernard A; Phelps C; Khokhar NZ; Knoblauch R; Parekh TV; Dirix L; Sharma S
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):729-37. PubMed ID: 25100135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.
    Halama B; Hohmann N; Burhenne J; Weiss J; Mikus G; Haefeli WE
    Clin Pharmacol Ther; 2013 Jun; 93(6):564-71. PubMed ID: 23511711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of systemic exposure to unbound docetaxel and neutropenia.
    Baker SD; Li J; ten Tije AJ; Figg WD; Graveland W; Verweij J; Sparreboom A
    Clin Pharmacol Ther; 2005 Jan; 77(1):43-53. PubMed ID: 15637530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
    Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
    Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.
    Sarantopoulos J; Mita AC; Wade JL; Morris JC; Rixe O; Mita MM; Dedieu JF; Wack C; Kassalow L; Lockhart AC
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1113-24. PubMed ID: 25307552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
    Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.
    Goh BC; Lee SC; Wang LZ; Fan L; Guo JY; Lamba J; Schuetz E; Lim R; Lim HL; Ong AB; Lee HS
    J Clin Oncol; 2002 Sep; 20(17):3683-90. PubMed ID: 12202670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
    Engels FK; Ten Tije AJ; Baker SD; Lee CK; Loos WJ; Vulto AG; Verweij J; Sparreboom A
    Clin Pharmacol Ther; 2004 May; 75(5):448-54. PubMed ID: 15116057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
    Chaobal HN; Kharasch ED
    Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
    Yong WP; Desai AA; Innocenti F; Ramirez J; Shepard D; Kobayashi K; House L; Fleming GF; Vogelzang NJ; Schilsky RL; Ratain MJ
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):811-9. PubMed ID: 17308893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.